Abstract:The present study describes the synthesis and biological evaluation of In-111(DOTA-3P-RGD(2)) (DOTA = 1,4,7,10-tetraazacyclo-dodecane-1,4,7,10-tetraacetic acid; 3P-RGD(2) = PEG(4)-E[PEG(4)-c(RGDfK)](2); PEG(4) = 15-amino-4,7,10,13-tetraoxapentadecanoic acid), In-111(DTPA-3P-RGD(2)) (DTPA = diethylenetriaminepentaacetic acid) and In-111(DTPA-Bn-3P-RGD(2)) (DTPA-Bn = 2-(p-thioureidobenzyl)-diethylenetriaminepentaacetic acid) as potential radiotracers for imaging tumor integrin alpha(v)beta(3) expression in athymic nude mice bearing U87MG glioma xenografts. The aim of the study is to assess the impact of the bifunctional chelator (BFC) (DOTA vs. DTPA or DTPA-Bn) on the biodistribution characteristics of the In-111-labeled 3P-RGD(2). IC50 values of DOTA-3P-RGD(2), DTPA-3P-RGD(2) and DTPA-Bn-3P-RGD(2) were determined to be 1.3 +/- A 0.2, 1.4 +/- A 0.3, 1.3 +/- A 0.3 nM, respectively, against I-125-c(RGDyK) bound to U87MG human glioma cells. Radiotracers were prepared by reacting (InCl3)-In-111 with the RGD peptide conjugates in NH4OAc buffer (100 mM, pH 5.5). For DOTA-3P-RGD(2), successful radiolabeling could be completed by heating the reaction mixture at 100A degrees C for 15-20 min. For DTPA-3P-RGD(2) and DTPA-Bn-3P-RGD(2), the radiolabeling was almost instantaneous at room temperature. The specific activity was similar to 50 mCi/mg (or similar to 100 mCi/mu mol) for In-111(DOTA-3P-RGD(2)) and similar to 200 mCi/mg (or similar to 400 mCi/mu mol) for In-111(DTPA-3P-RGD(2)). The results from biodistribution studies showed that all the three radiotracers have high tumor uptake and excellent tumor-to-background (T/B) ratios up to 4-h postinjection. After that time point, both In-111(DTPA-3P-RGD(2)) and In-111(DTPA-Bn-3P-RGD(2)) showed a much faster tumor washout and poorer T/B ratios than In-111(DOTA-3P-RGD(2)). The tumor uptake of In-111(DOTA-3P-RGD(2)) is integrin alpha(v)beta(3)- and RGD-specific. In-111(DOTA-3P-RGD(2)) is metabolically stable while only similar to 25% of In-111(DTPA-Bn-3P-RGD(2)) remains intact in the feces during 2-h period. On the basis of results from this study, it was concluded that In-111(DTPA-3P-RGD(2)) can be an effective integrin alpha(v)beta(3)-targeted radiotracer if the high-specific activity is required. However, DOTA remains to be the BFC of choice for the development of therapeutic lanthanide radiotracers.

Synthesis and Evaluation of a Cathepsin B–Recognizing Trifunctional Chelating Agent to Improve Tumor Retention of Radioimmunoconjugates

eTFC-01: a dual-labeled chelate-bridged tracer for SSTR2-positive tumors

Intracellular Construction of Cathepsin B-Guided Gadolinium Nanoparticles for Enhanced T2 -Weighted MR Tumor Imaging.

Improvement of tumor-to-blood ratio of radioimmunoconjugates by poly(ethyleneimine)-containing chelating agent

Impact Of Bifunctional Chelators On Biological Properties Of In-111-Labeled Cyclic Peptide Rgd Dimers

Synthesis and evaluation of novel trifunctional chelating agents for pretargeting approach using albumin binder to improve tumor accumulation

Synthesis of Site-Specific Radiolabeled Antibodies for Radioimmunotherapy Via Genetic Code Expansion.

Site-specific Conjugation of 6 DOTA Chelators to a CA19-9-targeting scFv-Fc Antibody for Imaging and Therapy

Synthesis and Evaluation Of111in-Dota-mab109 Monoclonal Antibody for Potential SPECT Molecular Imaging

Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates

Molecular Imaging of Cancer Using X-ray Computed Tomography with Protease Targeted Iodinated Activity-Based Probes

Cathepsin B-Activated PET Tracer for In Vivo Tumor Imaging

Impact of Bifunctional Chelators on Biological Properties of 111In-Labeled Cyclic Peptide RGD Dimers

[ 18 F]-C-SNAT4: an improved caspase-3-sensitive nanoaggregation PET tracer for imaging of tumor responses to chemo- and immunotherapies

In vivo near-infrared fluorescence and SPECT-CT imaging of colorectal Cancer using the bradykinin B2R-specific ligand icatibant

Design and Bio.Evaluation of Cu-64-Nota-Herceptin for Tumor Targeted Micro-Pet Imaging

Cryptophycin-55/52 based antibody-drug conjugates: Synthesis, efficacy, and mode of action studies

Tumor Site-Specific Cleavage Improves the Antitumor Efficacy of Antibody–Drug Conjugates

Improving Intracellular Delivery of an Antibody-Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo

Preparation and Evaluation of Tc-99m-Labeled Dimeric Tyr(3)-Octreotide in the Ar42j Tumor Model

Targeting of a CCK2 receptor splice variant with 111In-labelled cholecystokinin-8 (CCK8) and 111In-labelled minigastrin